According to a research report published by Lyon, Hewang Pharmaceutical authorized GSK the overseas rights for its KRAS-EGFR ATTC drug candidate HMPL-A830 and received a down payment of 110 million US dollars and a milestone payment of up to 1.3 billion US dollars. The bank believes that the deal is a strong recognition of the company's ATTC platform by multinational pharmaceutical companies. Lyon also believes that the ATTC portfolio's further proof of concept data and additional collaboration is a key catalyst worth watching. The bank reaffirmed the company's “outperforming the market” rating, and the target price remained at HK$29.5.

According to a research report published by Lyon, Hewang Pharmaceutical authorized GSK the overseas rights for its KRAS-EGFR ATTC drug candidate HMPL-A830 and received a down payment of 110 million US dollars and a milestone payment of up to 1.3 billion US dollars. The bank believes that the deal is a strong recognition of the company's ATTC platform by multinational pharmaceutical companies. Lyon also believes that the ATTC portfolio's further proof of concept data and additional collaboration is a key catalyst worth watching. The bank reaffirmed the company's “outperforming the market” rating, and the target price remained at HK$29.5.